About Alkermes PLC
Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis. Its products include ARISTADA, VIVITROL, RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION & INVEGA TRINZA, AMPYRA/FAMPYRA, BYDUREON, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, Aripiprazole Lauroxil Two-Month Dose, ALKS 7119 and RDB 1450. Its product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release technology.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Delivery
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: ALKS
- CUSIP: G0176710
- Previous Close: $53.29
- 50 Day Moving Average: $55.66
- 200 Day Moving Average: $52.17
- 52-Week Range: $27.14 - $60.74
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 74.01
- P/E Growth: -38.15
- Market Cap: $8.12B
- Outstanding Shares: 152,430,000
- Beta: 2.12
- Net Margins: -36.92%
- Return on Equity: -12.75%
- Return on Assets: -8.98%
Companies Related to Alkermes PLC:
- Debt-to-Equity Ratio: 0.23%
- Current Ratio: 4.24%
- Quick Ratio: 3.96%
What is Alkermes PLC's stock symbol?
Alkermes PLC trades on the NASDAQ under the ticker symbol "ALKS."
Where is Alkermes PLC's stock going? Where will Alkermes PLC's stock price be in 2017?
10 equities research analysts have issued 1 year target prices for Alkermes PLC's stock. Their forecasts range from $35.00 to $78.00. On average, they expect Alkermes PLC's share price to reach $61.27 in the next twelve months.
When will Alkermes PLC announce their earnings?
Alkermes PLC is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.
What are analysts saying about Alkermes PLC stock?
Here are some recent quotes from research analysts about Alkermes PLC stock:
According to Zacks Investment Research, "Alkermes boasts a diversified portfolio of products targeting major CNS disorders including schizophrenia, depression, addiction and multiple sclerosis. Revenues are driven not only by the company’s royalty and manufacturing business, but also by a strong performance of Vivitrol and Aristada. Alkermes sees both Vivitrol and Aristada as growth drivers. While Vivitrol should benefit from the newly passed legislation, CARA, securing reimbursement and access for Aristada also bodes well. Meanwhile, Alkermes’ progress with its pipeline has been impressive. Focus should be on the same as the company expects important data readouts over the next several quarters. Given its history of pipeline setbacks, any obstacle in the process of development of these candidates would weigh heavily on the stock. Stiff competition and dependence on partners remains a threat. Shares of the company have underperformed the broader industry year to date." (12/13/2016)
J P Morgan Chase & Co analysts commented, "Importantly 5461 continued to be well tolerated, in line with prior studies. ALKS plans to meet with the FDA in early 1Q17 to discuss filing, and we continue to think positive FORWARD-5 data makes the totality of the data approvable [...] Further confirmation of an NDA filing based on data in hand, as well as, clarity on the filing timeline will be key in 2017." (10/21/2016)
Morgan Stanley analysts commented, "We are raising our PT from $18 (11x old F17e of 1.64) to $23 (16x new F17e of $1.42) since downside from US MFA (antibiotic medicated feed additive) pressures appears limited." (9/2/2016)
Who owns Alkermes PLC stock?
Alkermes PLC's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), State Street Corp (2.46%), Franklin Resources Inc. (1.83%), Frontier Capital Management Co. LLC (0.62%), Federated Investors Inc. PA (0.53%) and Marshall Wace LLP (0.42%). Company insiders that own Alkermes PLC stock include David Joseph Gaffin, David W Anstice, Elliot Ehrich, Gordon G Pugh, Iain Michael Brown, James M Frates, Kathryn L Biberstein, Mark Stejbach, Michael J Landine, Paul J Mitchell, Rebecca Peterson, Richard F Pops, Robert A Breyer and Shane Cooke.
Who sold Alkermes PLC stock? Who is selling Alkermes PLC stock?
Alkermes PLC's stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Janus Capital Management LLC, Asset Management One Co. Ltd., Castleark Management LLC, Guggenheim Capital LLC, Frontier Capital Management Co. LLC, Numeric Investors LLC and Raymond James Financial Services Advisors Inc.. Company insiders that have sold Alkermes PLC stock in the last year include David Joseph Gaffin, Elliot Ehrich, Gordon G Pugh, Iain Michael Brown, James M Frates, Kathryn L Biberstein, Mark Stejbach, Michael J Landine, Paul J Mitchell, Richard F Pops, Robert A Breyer and Shane Cooke.
Who bought Alkermes PLC stock? Who is buying Alkermes PLC stock?
Alkermes PLC's stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Credit Agricole S A, A.R.T. Advisors LLC, Allianz Asset Management AG, State Street Corp, FMR LLC, Two Sigma Investments LP and Turner Investments LLC.
How do I buy Alkermes PLC stock?
Shares of Alkermes PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Alkermes PLC stock cost?
One share of Alkermes PLC stock can currently be purchased for approximately $53.29.